Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
The Pharma Letter3d
BridgeBio’s Beyonttra approved in Japan
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...
BridgeBio announces Japanese MHLW approved acoramidis for treating ATTR-CM
BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...
Zacks Investment Research on MSN5d
4 Tech Stocks Penetrating the Health and Fitness Wearables Market
The healthcare and fitness wearables landscape is transforming rapidly, with tech giants investing heavily to improve the ...